clinical trials

Upcoming events – Bayer and Merck look to vericiguat, and Akero bets on Nash
Upcoming events – Bayer and Merck look to vericiguat, and Akero bets on Nash
EP Vantage
Bayer
Merck
vericiguat
heart failure
AKR-001
Akero Therapeutics
clinical trials
NASH
Flag link:
Neuroptika announces enrollment of first patient in phase 2 clinical trial for dry eye disease
Neuroptika announces enrollment of first patient in phase 2 clinical trial for dry eye disease
Pharmaceutical Business Review
Neuroptika
dry eye disease
NRO-1
clinical trials
Flag link:
Abbott Commences MitraClip Clinical Trial for Underserved Patient Population
Abbott Commences MitraClip Clinical Trial for Underserved Patient Population
Xtalks
Abbott Labs
clinical trials
devices
MitraClip
Flag link:
Alexion to Start Pivotal Study on Ultomiris for ALS in Q1
Alexion to Start Pivotal Study on Ultomiris for ALS in Q1
Yahoo/Zacks.com
Alexion
ALS
Ultomiris
clinical trials
Flag link:
On Heels of the Sale of Five Vants, Roivant Launches New Company Lokavant
On Heels of the Sale of Five Vants, Roivant Launches New Company Lokavant
BioSpace
Roivant
Vivek Ramaswamy
clinical trials
Lokavant
Flag link:
AstraZeneca's Epanova flunks key heart risk trial, giving Amarin's rival Vascepa a leg up
AstraZeneca's Epanova flunks key heart risk trial, giving Amarin's rival Vascepa a leg up
Fierce Pharma
AstraZeneca
Amarin
Vascepa
Epanova
clinical trials
Flag link:
Allogene, SpringWorks to Test Drug Combo in Multiple Myeloma Trial
Allogene, SpringWorks to Test Drug Combo in Multiple Myeloma Trial
Xconomy
SpringWorks Therapeutics
Allogene
Multiple Myeloma
clinical trials
ALLO-715
nirogacestat
Flag link:
VBI Vaccines announces second pivotal phase 3 study of Sci-B-Vac meets primary and secondary endpoints
VBI Vaccines announces second pivotal phase 3 study of Sci-B-Vac meets primary and secondary endpoints
Pharmaceutical Business Review
VBI Vaccines
vaccines
clinical trials
Sci-B-Vac
ARO-HBV
Flag link:
Ultragenyx shares jump on 'better than expected' gene therapy data
Ultragenyx shares jump on 'better than expected' gene therapy data
Fierce Biotech
Ultragenyx
clinical trials
gene therapy
DTX301
Flag link:
Regeneron's bone disease drug delivers in phase 2, poised for FDA filing
Regeneron's bone disease drug delivers in phase 2, poised for FDA filing
Fierce Biotech
Regeneron
Rare Diseases
FDA
clinical trials
garetosmab
Flag link:
At 2020 deadline, progress in Patrick Soon-Shiong’s ‘cancer moonshot’ is hard to find
At 2020 deadline, progress in Patrick Soon-Shiong’s ‘cancer moonshot’ is hard to find
Stat
Dr. Patrick Soon-Shiong
cancer
clinical trials
Flag link:
Overview: CRISPR Technology Headed to Clinical Trials
Overview: CRISPR Technology Headed to Clinical Trials
BioSpace
CRISPR
Editas Medicine
clinical trials
Allergan
LCA10
Flag link:
Here's Why Sage Therapeutics Lost 53.3% in December
Here's Why Sage Therapeutics Lost 53.3% in December
Motley Fool
SAGE Therapeutics
SAGE-217
major depressive disorder
clinical trials
Flag link:
Four ways AI and machine learning will transform healthcare in 2020
Four ways AI and machine learning will transform healthcare in 2020
Pharmaforum
artificial intelligence
machine learning
speech recognitition
clinical trials
robotic surgery
diagnostics
Flag link:
Durect shares rocked by midstage psoriasis flop, shifts focus to liver disease
Durect shares rocked by midstage psoriasis flop, shifts focus to liver disease
Fierce Biotech
Durect
clinical trials
psoriasis
DUR-928
Flag link:
Incyte stock slammed after study fails to hit goal
Incyte stock slammed after study fails to hit goal
Marketwatch
Incyte
clinical trials
itacitinib
graft vs host disease
Flag link:
Wave tanks again as Huntington's clinical trial data underwhelm
Wave tanks again as Huntington's clinical trial data underwhelm
Fierce Biotech
Wave Life Sciences
Huntington's disease
clinical trials
WVE-120102
Flag link:
Savara gets FDA breakthrough status despite large, late-stage failure
Savara gets FDA breakthrough status despite large, late-stage failure
Endpoints
Savara
FDA
clinical trials
molgradex
aPAP
Flag link:
Spring Bank Pharma shares slide 45% premarket after it halts trial of treatment for hepatitis B virus
Spring Bank Pharma shares slide 45% premarket after it halts trial of treatment for hepatitis B virus
Marketwatch
Spring Bank Pharmaceuticals
hepatitis B
clinical trials
FDA
inarigivir soproxil
Flag link:
Spectrum Pharma Shares Slump After Lung-Cancer Drug Doesn't Meet Phase II Endpoint
Spectrum Pharma Shares Slump After Lung-Cancer Drug Doesn't Meet Phase II Endpoint
TheStreet.com
Spectrum Pharma
lung cancer
clinical trials
poziotinib
non-small cell lung cancer
Flag link:

Pages